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ABSTRACT 
We report a four-year-old girl presented with progressive linear scleroderma affecting 
the right leg. Biopsy specimen disclosed typical histopathological findings of localized 
scleroderma. Right leg magnetic resonance image (MRI) showed high signal areas on 
T2 weighted images on the subcutaneous fatty tissue, muscles, and bone marrow, 
suggesting that skin inflammation extended to the bone marrow. Oral corticosteroid 
therapy was instituted with improvement of both skin sclerosis and MRI findings. Our 
observations suggest that MRI examination should be considered in patents with 
localized scleroderma to evaluate the extension of the inflammation.  
 





Scleroderma is divided into two clinical entities: localized scleroderma and systemic 
sclerosis (SSc). Localized scleroderma differs from SSc in that it is not accompanied by 
Raynaud’s phenomenon, acrosclerosis, and internal organ involvement1. However, since 
autoimmune abnormalities of localized scleroderma have been well recognized, this 
disease has generally been considered to have an autoimmune background2. Extensive 
involvement of the subcutaneous tissue and underlying bony structures is known3. Here, 
we report a patient with localized scleroderma associated with the bone marrow 
inflammation revealed by the magnetic resonance image (MRI) examination.  
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CASE REPORT 
The patient was a four-year-old girl without family history of scleroderma. She had 
been clinically well until three years ago when she presented with swelling and sclerotic 
plaques associated with hypo- and hyperpigmentation on the right lower leg, which 
extended gradually to whole of the right leg. The lesions were not erythematous and did 
not exhibit lilac ring (Fig 1a, b). Skin abnormalities did not appear on the other parts of 
body. Raynaud’s phenomenon was absent. Mild ankylosis of the right knee and limp 
were noted. Hematochemical investigations including transaminases, alkaline 
phosphatase, creatinine, creatine kinase, and blood urea nitrogen were in the normal 
range. Aldolase levels were elevated to 19.6 IU/l (normal value, 1.6 to 13.1 IU/l) and 
serum procollagen III peptide (P-III-P) levels were 1.8 U/l (<1.0 U/ml). Positive 
antinuclear antibody (Ab) (1:80, a nucleolar pattern), increased anti-single-stranded 
deoxyribonucleic acid (ssDNA) Ab (49.6 AU/l; normal value, <25 AU/ml), and 
increased anticardiolipin Ab (20.6 U/ml; <10 U/ml) were observed. Anti-topoisomerase 
I Ab, anti-RNP Ab, anti-Sm Ab, anti-double-stranded DNA Ab, anti-SS-A Ab, anti-SS-B 
Ab, and lupus anticoagulant were all negative. Borrelia burgdorferi infection was 
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excluded based upon the absence of specific Ab. Skin biopsy showed thickened and 
increased collagen in the dermis and infiltration of lymphocytes and plasmacytes in the 
dermis, subcutaneous fatty tissue, and fascia, which confirmed the diagnosis of linear 
scleroderma (Fig 2a, b). MRI showed the widespread lesion with high signal intensity 
on T2 weighted images in subcutaneous fatty tissue, vastus intermedius, sartorius 
muscle, femur, tibia, and bone marrows beneath the skin lesion (Fig 3a, b). Bone 
destruction was not observed. A bone marrow biopsy specimen from her right ilium 
showed no neoplastic change. Renal and pulmonary function tests were performed with 
normal results. Treatment with oral prednisolone of 10 mg daily was instituted with 
improvement of her skin sclerosis. Then, the patient was treated with a consecutive 
tapering with oral prednisolone. Serum levels of aldolase, P-III-P, and anti-ssDNA Ab 
decreased to 6.8 IU/l, 1.0 U/l, and 2.6 AU/ml, respectively. MRI scans after eight 
months showed that the affected area was reduced compared with those before 
treatment (Fig 3c).     
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DISCUSSION  
Localized scleroderma is a connective tissue disorder that is limited to the skin and the 
underlying tissue. In localized scleroderma, lesions may extend to and can involve the 
underlying muscles and bones with disturbances in growth and ankylosis3. Recent MRI 
studies of patients with “en coup de sabre”, a variant of linear scleroderma, have 
revealed intracranial abnormalities, including multiple lesions with high signal intensity 
on T2 weighted images, cerebral atrophy, impression of the skull corresponding to the 
skin lesions4,5. In addition, brain histology has shown patchy perivascular and brain 
lymphocytic infiltration but not necrosis of vessel walls, suggesting that a inflammatory 
process is involved in the development of lesions4. In our case, MRI revealed that T2 
signal increase in the right leg extended to the bone marrow directly adjacent to the area 
of localized scleroderma. Bone marrow biopsy showed no neoplastic change, 
suggesting that it is an inflammatory lesion. In addition, MRI displayed reduction of the 
bone marrow lesions in parallel with her improvement of skin lesions by oral 
corticosteroid therapy. Thus, it is suggested that this osteomyelitis was the result of 
inflammation extended from skin. 
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Localized scleroderma is generally considered to have an autoimmune 
background because it is accompanied by various immunological abnormalities, such as 
antinuclear Ab, anti-ssDNA Ab, rheumatoid factor, anti-cardiolipin Ab, and lupus 
erythematosus cell phenomenon6,7. A previous study has shown that anti-cardiolipin Ab 
is elevated in localized scleroderma with high frequency and correlates with the disease 
severity7. The titer of anti-ssDNA Ab is well correlated with disease activity and 
responds to oral corticosteroid treatment in patients with severe muscle involvement2. In 
our patient, anti-ssDNA Ab levels were elevated and then decreased in parallel with 
skin improvement by steroid therapy. Furthermore, serum aldolase and P-III-P levels 
decreased after skin improvement. These findings suggest that not only anti-ssDNA Ab 
levels but also serum aldolase and P-III-P levels are associated with the disease activity.  
Bone marrow involvement of localized scleroderma has not been reported; 
however, it may be due to rare MRI examination in affected extremities. Therefore, 
bone marrow abnormalities should always be considered in patients with localized 
scleroderma of the extremities. Collectively, not only immunological examinations but 
also MRI may be useful to evaluate the disease activity and efficiency of the treatment. 
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FIGURE LEGENDS 
Figure 1. Patient at first visit. (a) Diffuse swelling with the presence of sclerotic plaques 
on the whole of her right leg. (b) Sclerotic plaques are associated with hypo- and 
hyperpigmentation. 
Figure 2. Biopsy of skin lesion. (hematoxylin-eosin stain) (a) Fibrosis and sclerosis are 
observed in the whole layer of the dermis. (b) Lymphocytes and plasmacytes infiltrate 
into the dermis.  
Figure 3. T2 weighted MRI findings. (a, b) Images before treatment show high signal 
intensity lesion of subcutaneous fatty tissue, vastus intermedius, sartorius muscle, femur, 
tibia, and those bone marrows. (c) Image at eight months after initiating oral 
corticosteroid therapy shows the reduction of the hyperintense lesion.  
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